2019 International Congress Archives - Page 73 of 217

GABA-A Receptor Positive Allosteric Modulators: Phase 2 Proof of Concept Studies of Brexanolone Injection and SAGE-217 in Essential Tremor

J. Paskavitz, A. Bullock, D. Nguyen, A. Smith, B. Farley, M. Quirk, I. Kaul, S. Li, A. Ellenbogen, C. Silber, J. Doherty, H. Colquhoun, S. Kanes (Cambridge, MA, USA)
Gait impairment in Parkinson’s Disease: An [123I]FP-CIT SPECT study

V. Suarez Contreras, Y. Tayyabah, S. Caminiti, M. Politis (London, United Kingdom)
Gait in Spinocerebellar Ataxia Type12 (SCA-12)

M. Narang, A. Srivastava, R. Aggarwal, R. Rajan, M. Faruq, M. Srivastava (Delhi, India)
Gait patterns may distinguish Parkinsonian patients with and without mild cognitive impairment: a data mining approach

M. Amboni, C. Ricciardi, C. de Santis, G. Ricciardelli, S. Cuoco, G. Improta, L. Iuppariello, G. Santangelo, M. Cesarelli, P. Barone (Baronissi (salerno), Italy)
Gamma-glutamyltransferase and the risk of Parkinson’s disease: A National Health Service big data analysis

D. Yoo, R. Kim, E. Jung, K. Han, C. Shin, J. Lee (Seoul, Republic of Korea)
Gastrointestinal disorders in various forms of parkinsonism

R. Matmurodov, KH. Khalimova, EL. Abduqodirov (Tashkent, Uzbekistan)
Gastrointestinal microbiome in Parkinson’s disease in a Bavarian cohort

F. Marxreiter, A. Cosma-Grigorov, H. Gassner, H. Meixner, Z. Kohl, M. Neurath, S. Wirtz, J. Winkler (Erlangen, Germany)
Gastrointestinal symptoms as a risk factor for the appearance of motor fluctuations in patients with advanced Parkinson disease

C. Borrue-Fernandez, M. Boimorto (San Sebastian Reyes, Spain)
Gastrointestinal symptoms predict cognitive decline in Parkinson’s Disease

A. Gonçalves, A. Mendes, N. Vila-Chã, I. Moreira, S. Cavaco (Porto, Portugal)
Gaze – evoked nystagmus in PSP patients: Is it really atiypical? A case series of eight patients

MK. Klarendic, MA. Hribar, SB. Battelino, MGK. Kramberger, MK. Kojovic (Ljubljana, Slovenia)
GBA and ATP13A mutation and PD: clinical phenotype, eye movements and pathogenic implications

GM. Riboldi, J. Martone, J. Rucker, JR. Rizzo, T. Hudson, W. Dauer, S. Frucht (New York, NY, USA)
GBA mutation: Linking Parkinson’s and Gaucher’s Diseases

C. Sarabia-Tapia, S. Lopez-Alamillo, N. Monroy-Jaramillo, D. Davila-Ortiz, M. Rodriguez-Violante, A. Cervantes-Arriaga (Mexico City, Mexico)
GBA p.Glu326Lys substitution increases the risk to develop Parkinson’s disease; is it enough to affect disease phenotype?

O. Goldstein, M. Gana- Weisz, D. Cohen-Avinoam, A. Bar-Shira, A. Thaler, T. Shiner, A. Mirelman, N. Giladi, A. Orr-Urtreger (Tel Aviv, Israel)
GBA-LRRK2 Parkinson’s Disease: a clinical case

L. Azevedo Kauppila, D. Pimenta Silva, A. Castro Caldas, M. Coelho, J. Ferreira, L. Correia Guedes (Lisboa, Portugal)
GBA1 biomarkers in longitudinal CSF: GCase, Sphingolipids and alpha-synuclein

S. Lerche, C. Schulte, G. Machetanz, I. Wurster, B. Röben, M. Zimmermann, C. Deuschle, A. Hauser, I. Liepelt-Scarfone, J. Böhringer, I. Krägeloh-Mann, I. Lachmann, W. Maetzler, T. Gasser, M. Mielke, D. Berg, K. Brockmann (Tuebingen, Germany)
Gender differences for Motor and non motor symptoms in Parkinson’s Disease among Pakistani population

S. Naureen, A. Arshad, N. Ahmad (Islamabad, Pakistan)
Gender differences in Motor symptoms, Non-Motor symptoms and Quality of Life in Parkinson’s disease: COPPADIS-2015 study cohort

M. Aguilar, P. Pastor, B. Solano, I. Cabo, MJ. Catalan, V. Nogueira, V. Puente, JM. Garcia, R. Perez, C. Borrué, M. Mata, M. Alvarez, AB. Rodriguez, L. Vela, Y. Macías, MJ. Marti, P. Martinez, D. Santos (Sabadell, Spain)
Gender differences of fatigue characteristics in people with Parkinson’s disease

G. Cilga, T. Kahraman, AC. Kalkan, B. Donmez Colakoglu, A. Genc (Manisa, Turkey)
Gender gap in scientific granting competitions in movement disorders – insights from a national Canadian funding agency

S. Appel-Cresswell, P. Blanchet, J. Wysocki, R. Postuma (Vancouver, BC, Canada)
Gender-dependent improvement in the survival of Parkinson’s disease patients in Finland

T. Kuusimäki, S. Kurki, J. Sipilä, H. Salminen-Mankonen, O. Carpén, V. Kaasinen (Turku, Finland)
Gender-specific effects of uric acid on the development of freezing of gait in Parkinson’s disease

JH. Jung, SJ. Chung, YH. Sohn, PH. Lee (Seoul, Republic of Korea)
Gene Expression Profiling of depression in Huntington’s disease

G. Colpo, N. Rocha, E. Furr Stimming, A. Lucio (Houston, TX, USA)
Gene panel testing in movement disorders: an efficient approach highlighting overlaps and heterogeneity

S. Montaut, C. Tranchant, N. Drouot, G. Rudolf, C. Guissart, J. Tarabeux, T. Stemmelen, A. Velt, C. Fourrage, P. Nitschke, B. Gerard, JL. Mandel, M. Koenig, J. Chelly, M. Anheim (Paris, France)
Generalised Polymyoclonus In a Patient With Central Nervous System Tuberculosis

K. Shahedah, MS. Mohamad Salmi (Pahang, Malaysia)
Genetic analysis of DNA methylation and hydroxymethylation genes in Parkinson’s disease

L. Qin, L. Shu, B. Tang, Q. Xu (Changsha, China)
Genetic and clinical investigation of young onset dystonia in Korea: What can we learn?

JW. Cho, M. Kim, JK. Park, J. Ahn, J. Youn (Seoul, Republic of Korea)
Genetic diagnosis of Chorea-acanthocytosis using whole exome sequencing revealed novel VPS13A Gene mutation

H. Ryu, C. Hong, J. Lee (Daegu, Republic of Korea)
Genetic markers revealed in dysregulated pathways in ischemic stroke may lead to Parkinson’s disease

H. Singh, V. Swarup, A. Srivastava (Marseille, France)
Genetic panel testing in Parkinson’s disease

T. Toomsoo, I. Rubanovich, I. Kalju, S. Ott, A. Lindmäe, M. Mällo, K. Jaakson, K. Joost, K. Vender (Tallinn, Estonia)
Genetic polymorphism (rs6971) in translocator protein (TSPO) and its clinical relevance in Parkinson’s disease

P. Surathi, M. Matarazzo, A. Sethi, J. Mckenzie, N. Neilson, R. Ross, M. Schulzer, M. Farrer, S. Booromand, J. Stoessl (Vancouver, BC, Canada)
Genetic study of patients with Parkinson’s disease subjected to second line therapies

F. Carrillo, S. Jesus, T. Periñan, R. Escuela, D. Buiza, MA. Labrador, M. Carrión, A. Adarmes, D. Macias, P. Gomez-Garre, P. Mir (Seville, Spain)
Genetics and phenotypes of recessive parkinsonism in French and North African populations

S. Lesage, A. Lunati, M. Houot, S. Benromdhan, C. Tesson, F. Clot, C. Mhiri, E. Lohmann, JC. Corvol, A. Brice (Paris, France)
Genetics of Parkinson’s in India – Young Onset Parkinson’s Disease (GOPI-YOPD) – A Preliminary Demographic profile

P. Kukkle, V. Goyal, R. Kandadai, R. Borgohain, H. Kumar, A. Mukherjee, A. Biswas, S. Das, U. Muthane, S. Desai, P. Wadia, P. Pal, R. Yadav, V. Ramprasad (Bangalore, India)
Genomic variants associated with cognitive impairment in Parkinson’s disease: Ethnicity-specific GWAS

SJ. Chung, N. Choi, J. Kim, K. Kim, MJ. Kim, YJ. Kim, HS. Ryu, KW. Park (Anyang, Republic of Korea)
Genotype influences circuit compensation in Parkinson’s disease

K. Schindlbeck, A. Vo, N. Nguyen, C. Tang, M. Niethammer, V. Dhawan, V. Brandt, R. Saunders-Pullman, S. Bressman, D. Eidelberg (Manhasset, NY, USA)
Genotype-Phenotype correlations of Episodic Ataxia (EA). MDSGene Systematic Review

A. Shetty, K. Nabieva, F. Zeldenrust, A. Rasheed, J. Huang, S. Petkovic, K. Lohmann, C. Klein, C. Marras, O. Waln (Lübeck, Germany)
Genotype-phenotype relations for the isolated Dystonia Genes TOR1A, THAP1, GNAL, ANO3, KMT2B, PRKRA and HPCA: MDSGene Systematic Review

LM. Lange, J. Junker, S. Loens, L. Olschewski, S. Schaake, S. Petkovic, M. Kasten, A. Westenberger, A. Domingo, A. Madoev, I. König, C. Marras, KP. Bhatia, S. Camargos, C. Klein, K. Lohmann (Lübeck, Germany)
Geste antagoniste in Catalan art – Santiago Rusiñol’s Laughing Girl

F. Germiniani, P. Marques, L. Pinheiro, G. Franklin, G. Ribas, H. Teive (Curitiba, Brazil)
Ginsenoside Rb1 Prevents MPTP-Induced Changes in Hippocampal Memory via Regulation of the α-Synuclein/PSD-95 Pathway

S. Qu, Y. Zhang, X. Meng, Y. Liu, X. Zhang (Foshan, China)
Glabellar tap predicts dopamine transporter deficiency in parkinsonism

S. Nuuttila, J. Joutsa, M. Eklund, E. Jaakkola, E. Mäkinen, T. Noponen, T. Ihalainen, F. Scheperjans, V. Kaasinen (Turku, Finland)
Global implementation of efficacious voice treatment for Parkinson’s disease: LSVT LOUD in Germany, France and Japan

L. Ramig, T. Brauer, C. Airiau, M. Fujiu-Kurachi (Boulder, CO, USA)
GluRδ2 protein reduction in cerebellar Purkinje cells contributes to the pathogenesis of essential tremor

MK. Pan, YS. Li, CL. Ni, WC. Liu, E. Cortes, JP. Vonsattel, E. Louis, P. Faust, SH. Kuo (Taipei, Taiwan)
GLYCOPAR – A randomized, placebo-controlled, 2-arm parallel-group superiority phase II study of glycopyrrolate for moderate-to-severe sialorrhea in Parkinson’s disease

T. Mestre, E. Freitas, M. Lopez, A. Basndwah, L. de Oliveira, D. Al-Shorafat, Z. Alarfaz, H. Shinawi, S. Reddie, D. Mancini, J. Lui, D. Grimes, S. Fox (Ottawa, ON, Canada)
Glycopyrrolate as inhalation for treating sialorrhea in Parkinson’s Disease

L. Velzen, J. Masselink, L. Dorresteijn, K. Movig (Enschede, Netherlands)
Glymphatic system activity in Parkinson’s disease: diffusion tensor image analysis along the perivascular space (DTI‑ALPS)

JM. Kim, YJ. Bae (Seongnam, Republic of Korea)
GNAO1 gene mutation: generalized dystonia without epilepsy.

Z. Guduru, T. Ali, J. Gurwell, D. Ginjupally (Lexington, KY, USA)
Goal setting for botulinum toxin injections: Impact of the Upper Limb International Spasticity (ULIS) programme

K. Fheodoroff, S. Ashford, J. Jacinto, A. Brashear, P. Maisonobe, A. Lysandropoulos, L. Turner-Stokes (Hermagor, Austria)
Gocovri Dose Adjustment in Elderly Parkinson’s Patients at Risk for Renal Impairment: Implications from an Exposure Simulation Model

I. Isaacson, A. Mittur, R. Patni (Boca Raton, FL, USA)
GPi DBS does not affect sensory thresholds in hereditary/idiopathic dystonia

C. Listik, R. Gisbert Cury, V. da Silva, S. Carvalho Barbosa Casagrande, E. Listik, L. Link, R. Galhardoni, E. Reis Barbosa, M. Jacobsen Teixeira, D. de Andrade (Sao Paulo, Brazil)
Gray Matter Abnormalities in Parkinson’s disease: a Voxel-wise meta-analysis

XR. Xu, Q. Han, JY. Lin, L. Wang, HF. Shang (Chengdu, China)
Gray matter atrophy in Parkinson’s disease and freezing of gait assessed using surface-based algorithm – results of an open, longitudinal, single-centre study

P.. Kanovsky, M.. Vastik, K.. Mensikova, P.. Hok, J.. Valosek, P.. Hlustik (Olomouc, Czech Republic)
Gray matter substrates of depression in blepharospasm

J. Yang, YB. Hou, QQ. Wei, RW. Ou, W. Song, B. Cao, HF. Shang (Chengdu, China)
Grey matter atrophy in Parkinson’s disease with long-duration response

G. Donzuso, G. Sciacca, G. Mostile, A. Nicoletti, M. Zappia (Catania, Italy)
Grey-matter volume changes underpinning irritability and aggression in early manifest Huntington’s disease

S. Martinez-Horta, F. Sampedro, J. Perez-Perez, A. Horta-Barba, J. Pagonabarraga, J. Kulisevsky (Barcelona, Spain)
Guided Self-rehabilitation Contracts combined with simultaneous injections of abobotulinumtoxinA into upper and lower limbs in spastic hemiparesis: baseline data from the ENGAGE study

J-M. Gracies, G. Francisco, R. Jech, S. Khatkova, C. Rios, P. Maisonobe (Créteil, France)
Gustatory Connectivity in Parkinson’s Disease Progression

H. Chatterjee, G. Elumalai, N. Sewram, N. Osakwe (Georgetown, Guyana)
Gut Feelings about Parkinson’s Disease: The Influence of the Gut Microbiota in a Rodent Model

A. Gorecki, L. Preskey, M. Bakeberg, J. Kenna, C. Gildenhuys, S. Dunlop, F. Koengten, R. Anderton (Nedlands, Australia)
Gut microbiota in Parkinson disease with mild cognition impairment in a southern Chinese cohort.

TZ. Ren, K. Nie, LJ. Wang (Guangzhou, China)
Gut problems in Huntington’s disease? Evidence for a leaky gut in the R6/2 mouse model of HD

TL. Stan, N. Franke, M. Sjögren, M. Björkqvist (Lund, Sweden)